相关实验视频

Updated: May 5, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

在接受皮肤冠状动脉干预的患者中,P2Y12抑制剂预治疗对支架血栓的影响:法国PCI注册表的洞察力

Grégoire Rangé¹, Guillaume Cayla², Denis Angoulvant³

¹Cardiology Department, Les Hôpitaux de Chartres, Chartres, France.

The Canadian journal of cardiology

|October 31, 2025

概括

在皮肤冠状动脉干预 (PCI) 之前先用P2Y12抑制剂预治疗患者,可显著减少支架血栓形成,改善治疗结果. 这种双重抗血小板疗法 (DAPT) 方法在现实数据中显示,在不增加重大出血风险的情况下显示出好处.

科学领域:

心脏病学心脏病学
干预心脏病学干预心脏病学
药理学药理学是指药理学的学科.

背景情况:

在皮肤冠状动脉干预 (PCI) 之前,对启动P2Y12抑制剂治疗的最佳时间进行了讨论.
双抗血小板治疗 (DAPT) 预治疗对早期支架血栓形成的影响需要进一步调查.
专注于患有慢性冠状动脉综合征和非ST升高心肌梗塞的患者进行PCI.

研究的目的:

分析P2Y12抑制剂预治疗对早发性支架血栓形成的影响.
评估DAPT预治疗对PCI后临床结果的影响.
评估与DAPT预治疗相关的安全概况,特别是重大出血事件.

主要方法:

从"法国PCI"注册表 (2014-2020年) 中回顾分析了53,898个PCI程序.
患者队列:P2Y12抑制剂预治疗 (83.2%) 与没有预治疗 (16.8%).
主要终点:医院内明确的支架血栓;次要终点:主要的不良心血管事件,全因死亡率和重大出血.

主要成果:

P2Y12抑制剂预治疗显著降低了住院支架血栓形成的可能性 (0.1%对0.4%;或0.35).
一年后的结果有利于预治疗:减少主要心血管不良事件 (6.6%vs. 7.8%) 和全因死亡率 (4.6%vs. 6.0%).
在预治疗组中没有观察到重大出血事件的显著增加.

结论:

在PCI患者中,P2Y12抑制剂预治疗与减少住院支架血栓形成有关.
预治疗改善了1年的临床结果,包括心血管事件和死亡率,而不会增加出血风险.
选择性抗血小板预治疗可能是一个有价值的策略,以提高PCI患者的缺血结局.

关键词:

这是一种P2Y12抑制剂.双重抗血小板疗法双重抗血小板疗法通过皮肤进行冠状动脉干预.预处理预处理支架凝血症支架凝血症

更多相关视频

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Acute Coronary Syndrome III: Diagnostic Studies

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...